

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK

ATTORNEY'S DOCKET NUMBER

524012000200

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. § 371**

U S APPLICATION NO (If known, see 37 CFR 1.5)

09/980672

INTERNATIONAL APPLICATION NO.

PCT/AU99/01137

INTERNATIONAL FILING DATE

DECEMBER 21, 1999

PRIORITY DATE CLAIMED

DECEMBER 21, 1998

TITLE OF INVENTION

CARDIAC MUSCLE FUNCTION AND MANIPULATION

APPLICANT(S) FOR DO/EO/US

Mingdong ZHOU

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☐ The US has been elected by the expiration of 19 months from the priority date (PCT Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☒ is attached hereto (required only if not communicated by the International Bureau)
 - b. ☐ has been communicated by the International Bureau
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application under PCT Article 19 (35 U.S.C. 371(c)(2)).
 - a. ☐ is attached hereto
 - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau
 - c. ☐ have not been made, however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A FIRST preliminary amendment
14. ☐ A SECOND or SUBSEQUENT preliminary amendment
15. ☐ A substitute specification
16. ☐ A change of power of attorney and/or address letter
17. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter 2 and 35 U.S.C. 1.821 - 1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4)
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☐ Other items or information:

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Express Mail Label No. EL 832761760 US Date of Deposit: October 23, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

RHEA AMID

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) * <div style="font-size: 1.5em; font-weight: bold; margin-top: 5px;">09/980672</div>		INTERNATIONAL APPLICATION NO. PCT/AU99/01137		ATTORNEY'S DOCKET NUMBER 524012000200	
---	--	--	--	---------------------------------------	--

21. <input type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO.....\$1,040.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO.....\$890.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....\$740.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provision of PCT Article 33(1)-(4)\$710.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)\$100.00				CALCULATIONS PTO USE ONLY	
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$1040.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$ 130.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$*	
Total claims	29 - 20 =	9	x \$18.00	\$162.00	
Independent claims	10 - 3 =	7	x \$84.00	\$588.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$280.00	\$*	
TOTAL OF ABOVE CALCULATIONS =				\$1920.00	
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$ 960.00	
SUBTOTAL =				\$ 960.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$*	
TOTAL NATIONAL FEE =				\$*	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$*	
TOTAL FEES ENCLOSED =				\$960.00	
				Amount to be refunded:	
				charged:	\$ 960.00

a. ☐ A check in the amount of \$* to cover the above fees is enclosed.

b. ☒ Please charge my Deposit Account No. 03-1952, ref Docket No. 524012000200 in the amount of \$960.00 to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees that may be required, or credit any overpayment to Deposit Account No. 03-1952, ref Docket No. 524012000200. A duplicate copy of this sheet is enclosed.

d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Peng Chen
 Morrison & Foerster LLP
 3811 Valley Centre Drive
 Suite 500
 San Diego, California 92130-2332

SIGNATURE

 Peng Chen
 Registration No. (43,543)

09/980,672
JC20 Rec'd PCT/PTO 06 MAY 2002

09/980,672
PATENT
Docket No 524012000200

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Express Mail Label No EL 796956151 US

Date of Deposit May 6, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: U.S. Patent and Trademark Office, Box PCT, Washington, D.C. 20231


Irina Britva

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Mingdong ZHOU

Serial No.: 09/980,672

Filing Date: October 23, 2001

For: CARDIAC MUSCLE FUNCTION AND
MANIPULATION

Examiner: To be Assigned

Group Art Unit: To be Assigned

TRANSMITTAL

Box PCT
Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Attached hereto for filing are the following:

1. Response to Notification of Missing Requirements under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US)
2. Copy of Notification of Missing Requirements under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US)
3. A paper copy of the substitute Sequence Listing
4. A computer readable form copy of the substitute Sequence Listing

sd-90747

on CD-R (CRF COPY)
-Machine format: IBM PC COMPATIBLE
-Operating system: PC-DOS/MS-DOS
-File contained on CD: 5240120002.txt
-Date recorded: May 6, 2002


5. Return Postcard

In the unlikely event that the Patent Office determines that extensions and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or fees due to our Deposit Account No. 03-1952 under Order No. 524012000200 The Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: May 6, 2002

By:


Peng Chen
Registration No. 43,543

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5117
Facsimile: (858) 720-5125

In the Sequence Listing:

Please replace the paper copy of the previously submitted sequence listing with the paper copy of the substitute sequence listing submitted herewith. A computer readable form copy of the substitute sequence listing accompanies this response.

REMARKS


The undersigned hereby states that the paper copy of the substitute Sequence Listing and the computer readable form copy of the substitute Sequence Listing, submitted in accordance with 37 C.F.R. § 1.825(a) and (b), respectively, are the same and contain no new matter. Accordingly, entry of the substitute Sequence Listing into the above-captioned application is respectfully requested.

In the unlikely event that the patent office determines that extensions and/or other relief is required, applicant petition for any required relief including extensions of time and authorize the assistant commissioner to charge the cost of such petitions and/or fees due to our deposit account no. 03-1952 under order no. 524012000200. The assistant commissioner is not authorized to charge the cost of the issue fee to the deposit account.

Respectfully submitted,

Date: May 6, 2002

By:


Peng Chen
Registration No. 43,543

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5117
Facsimile: (858) 720-5125

SEQUENCE LISTING

<110> Zensun (Shanghai) Science & Tech. Ltd
Zhou, Mingdong

<120> CARDIAC MUSCLE FUNCTION AND MANIPULATION

<130> 52401-20002.00

<140> US 09/980,672

<141> 2001-10-23

<150> PCT/AU 99/01137

<151> 1999-12-21

<150> AU 1998 PPO 07850

<151> 1998-12-21

<160> 2

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 114

<212> DNA

<213> Homo sapiens

<400> 1

agccatcttg	taaatgtgcg	gagaaggaga	aaactttctg	tgtgaatgga	ggggagtgc	60
tcattggtgaa	agacctttca	aaccctcga	gatacttg	aggagctgta	ccag	114

<210> 2

<211> 58

<212> PRT

<213> Homo sapiens

<400> 2

Ser	His	Leu	Val	Lys	Cys	Ala	Glu	Lys	Thr	Phe	Cys	Val	Asn	Gly	Gly
1				5				10					15		
Glu	Cys	Phe	Met	Val	Lys	Asp	Leu	Ser	Asn	Pro	Ser	Arg	Tyr	Leu	Cys
			20					25					30		
Lys	Cys	Pro	Asn	Glu	Phe	Thr	Gly	Asp	Arg	Cys	Gln	Asn	Tyr	Val	Met
			35				40					45			
Ala	Ser	Phe	Tyr	Lys	Ala	Glu	Glu	Leu	Tyr						
50							55								


09/980672
JC10 DocId:35040200 2001

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Express Mail Label No.: EL 832761760 US

Date of Deposit: October 23 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.


Rhea Amid

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Mingdong ZHOU

Serial No.: National Stage of PCT/AU99/01137

Filing Date: Herewith

For: **CARDIAC MUSCLE FUNCTION AND
MANIPULATION**

Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Preliminary to the examination of the above-captioned application, please amend the application as follows.

IN THE CLAIMS:

Please replace claims 3-5 with the following clean set of amended claims 3-5. A mark-up version of the amended claims 3-5 is attached hereto as Exhibit A.

3. (Amended) The method according to claim 1 wherein neuregulin is provided directly to the cardiac cell or provided indirectly by causing neuregulin to be produced in other cells by inducing expression of the gene (s) involved in neuregulin production.

sd-62764

4. (Amended) The method according to claim 1 wherein neuregulin production is in the cardiac muscle cell to which the method is directed in an autocrine manner or produced by some other cell and released in a paracrine manner.

5. (Amended) The method according to claim 1 wherein function of a normal or diseased heart is improved by the treatment with neuregulin.

Please add the following new claims 25-29:

25. (New) The method according to claim 2 wherein neuregulin is provided directly to the cardiac cell or provided indirectly by causing neuregulin to be produced in other cells by inducing expression of the gene (s) involved in neuregulin production.

26. (New) The method according to claim 2 wherein neuregulin production is in the cardiac muscle cell to which the method is directed in an autocrine manner or produced by some other cell and released in a paracrine manner.

27. (New) The method according to claim 2 wherein function of a normal or diseased heart is improved by the treatment with neuregulin.

28. (New) The method according to claim 3 wherein function of a normal or diseased heart is improved by the treatment with neuregulin.

29. (New) The method according to claim 4 wherein function of a normal or diseased heart is improved by the treatment with neuregulin.


REMARKS

Upon entry of the present Preliminary Amendment, claims 1-29 will be pending. Claims 3-5 are amended and new claims 25-29 are added to remove multiple dependency in the original claims 3-5. Therefore, the above-described amendments do not introduce any new matter into the present application.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket no. 524012000200. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: October 23, 2001

By: 
 Peng Chen
 Registration No. 43,543

Morrison & Foerster LLP
 3811 Valley Centre Drive, # 500
 San Diego, CA 92130-2332
 Telephone: (858) 720-5117
 Facsimile: (858) 720-5125

(The following information was obtained from the records of the Federal Bureau of Investigation, Department of Justice.)

4. (Amended) The method according to claim 1 [or 2] wherein neuregulin production is in the cardiac muscle cell to which the method is directed in an autocrine manner or produced by some other cell and released in a paracrine manner.

6/ppts

1

Cardiac Muscle Function and ManipulationTechnical Field

This invention relates to polypeptides which affect myocardial cell differentiation and organisation of cardiac muscle contractile units, assay for
5 identifying such polypeptides, and methods for improving cardiac function by the administration of such polypeptides to patients with heart disease.

Background of the Invention

Heart failure affects 1.5% of populations, approximately three million
10 Americans, developing at a rate of approximately 400,000 new cases per year in USA. Current therapy for heart failure is primarily directed to using angiotensin-converting enzyme (ACE) inhibitors and diuretics. ACE inhibitors appear to slow progress to end-stage heart failure; however, they are unable to relieve symptoms in more than 60% of heart failure patients and reduce mortality of heart failure only by approximately 15-20%. Heart
15 transplantation is limited by the availability of donor hearts. With the exception of digoxin, the chronic administration of positive inotropic agents has not resulted in a useful drug without adverse side effects, including increased arrhythmias, or sudden death. These deficiencies in current therapy suggest the need for additional therapeutic approaches.

20 Growth of cardiac muscle cells switches from proliferation to hypertrophy during heart development. The former process is characterised by an increase in cardiac muscle cell number, and the latter by an increase in cell size without DNA synthesis or cell division. This switch is associated with terminal differentiation of cardiac muscle cells and occurs gradually
25 during heart development, starting during the late embryonic stages and ending a few weeks after birth. During this period, gene expression, particularly that involving the cell cycle and signalling, is reprogrammed. For example, expression of a number of receptor protein tyrosine kinases and other cell cycle components decreases. Cell phenotype is also changed as
30 cell-cell adhesions and contractile proteins are more organised in terminal differentiated myocardial cells.

Adult heart hypertrophy is an important adaptive physiological response to increased demands for cardiac work or after a variety of
pathological stimuli that lead to cardiac injury. Normal hypertrophic cells
35 have a large size with increased and well organised contractile units, as well as strong cell-cell adhesions. Although pathologically hypertrophic cells also

5

10

20

35



cell differentiation and secretion of milk proteins; induction of neural crest cell differentiation to Schwann cells; stimulation of skeletal muscle cell synthesis of acetylcholine receptors; and, promotion of myocardial cell survival and DNA synthesis. *In vivo* studies of neuregulin gene-targeted homozygous mouse embryos with severe defects in ventricular trabeculae formation and dorsal root ganglia development indicate that neuregulin is essential for heart and neural development. However, information on how neuregulin controls cell differentiation and its downstream signalling pathways is limited.

Within the heart, neuregulin and ErbB receptors are respectively expressed in the endocardial lining and cardiac muscle layer in early stages of development. Since these two layers are widely separated, the neuregulin ligand must transverse the space between the two cell layers to activate their cognate ErbB receptors. Activation of these receptors in myocardial cells is necessary for promoting muscle cell growth or migration toward the endocardium, which results in the formation of finger-like structures (ventricular trabeculae) between these two layers. It is not clear previously if neuregulin stimulates myocardial cell differentiation.

The present inventor has now found that neuregulin and/or its cellular action may be suitable for use in detection, diagnosis and treatment of heart disease. Moreover, the inventor believes that potential beneficial effects of neuregulin and/or its cellular action may be specific for heart muscle cells and not necessarily applicable to skeletal or smooth muscle cells since 1) heart, skeletal and smooth muscle are both embryological and functionally distinct; 2) factors involved in skeletal muscle growth and differentiation, such as MyoD, play little or no role in cardiac muscle growth and differentiation; 3) inactivation of the genes for ErbB2 or 4 receptors or neuregulin produces major defects in cardiac but not skeletal or smooth muscle development, 4) as shown here, the growth factor, insulin like growth factor-I (IGF-I) causes embryonic myocyte proliferation but unlike neuregulin does not stimulate differentiation of these cells. By contrast, IGF-I but not neuregulin, has been shown to induce muscle hypertrophy.

Summary of the Invention

The present invention is based in part on the discovery that neuregulin enhances cardiac muscle cell differentiation and organisation of sarcomeric and cytoskeleton structures, as well as cell-cell adhesion. Neuregulin, 5 neuregulin polypeptide, neuregulin derivatives, or compounds which mimic the activities of neuregulins, fall within the scope of the methods of the present invention and are abbreviated hereinafter as NRG.

In a first aspect, the present invention consists in a method of causing cardiomyocyte growth and/or differentiation, the method comprising 10 exposing the cardiomyocyte to NRG thereby activating the MAP kinase pathway in the cardiomyocyte and causing growth and/or differentiation of the cardiomyocyte.

In a second aspect, the present invention consists in a method of inducing remodelling of muscle cell sarcomeric and cytoskeleton structures, 15 or cell-cell adhesions, the method comprising treating the cells with neuregulin thereby activating the MAP kinase pathway in the cells and causing remodelling of the cell structures or the cell-cell adhesions.

It will be appreciated that neuregulin may be provided directly to the cell or provided indirectly by causing neuregulin to be produced in cells by 20 inducing expression of the gene(s) involved in neuregulin production. The production may be in the same cell to which the method is directed in an autocrine manner or by some other cell in a paracrine manner.

In a third aspect, the present invention consists in a method of identifying polypeptides or compounds which stimulate cardiac muscle cell 25 differentiation, the method comprising contacting the cardiac muscle with a test polypeptide or compound in the presence of an inducer of cardiac muscle cell proliferation in the form of neuregulin, and measuring the development of cardiac muscle cell differentiation.

The differentiation of cardiac muscle cells is preferably measured in 30 cells exposed to neuregulin or other test polypeptides, or to a mixture of neuregulin with a test polypeptide. Differentiation of cardiac muscle cell can be measured in a variety of ways, including by calculation of increases or decreases in DNA synthesis, analysis of the time-course of phosphorylation of MAP kinases in cardiac muscle cells, evaluation of the expression of cell 35 cycle inhibitor, p21^{CIP1}, phenotypic organisation of contractile units,

accumulation of contractile units, phenotypic alteration of cytoskeleton actin fibers, and the phenotype of cell-cell adhesions.

In one preferred embodiment of the method of identifying polypeptides or compounds which stimulate cardiac muscle cell differentiation, cells are
5 incubated with different concentrations of various peptides or compounds and the effect of the test peptide or compound in different concentrations on cardiac muscle cell differentiation measured.

In another preferred embodiment of identifying polypeptides or compounds which induce cardiac muscle cell differentiation that dominates
10 over that of the putative inducer of cardiac muscle cell proliferation, insulin-like growth factor-1 (IGF-1), cells are incubated with IGF-1, with and without the test polypeptide or compound, and the ability of the test polypeptide or compound to inhibit IGF-1-mediated cardiac muscle cell DNA synthesis, assembly of sarcomeric structures and cell-cell adhesions are measured.

In a further embodiment, the cells are incubated with phenylephrine
15 (PE) with and without the test polypeptide or compound, and the ability of the test polypeptide or compound to augment PE-mediated cardiac muscle cell differentiation is determined. A test polypeptide which stimulates cardiac muscle cell differentiation may stimulate the assembly of sarcomeres and thus enhance heart function in a variety of ways, including by activating
20 neuregulin-specific receptors, e.g., ErbB2, ERbB3 and ErbB4.

In a fourth aspect, the present invention consists in a method of identifying polypeptides or compounds which inhibit neuregulin stimulation
25 of ventricular muscle cell differentiation, the method comprising contacting the ventricular muscle cell with the test polypeptide or compound in the presence neuregulin and measuring any inhibition of neuregulin stimulation of the ventricular muscle cell.

A compound may inhibit neuregulin stimulation of ventricular muscle cell differentiation by blocking, suppressing, reversing, or antagonising the
30 action of neuregulin. In one embodiment, the measurement is by detecting DNA synthesis of ventricular muscle cells.

In a fifth aspect, the present invention consists in a therapeutic
35 method of treating or preventing disassociation of cardiac muscle cell-cell adhesion and/or the disarray of sarcomeric structures in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a neuregulin or its derivatives.

In one preferred embodiment, the therapeutic method is directed to treating heart failure resulting from disassociation of cardiac muscle cell-cell adhesion and/or the disarray of sarcomeric structures in the mammal.

5 In a sixth aspect, the present invention consists in a method of preventing or lowering the incidence of heart disease in a mammal, the method comprising preventing or lowering the interference or effects of polypeptides or compounds on the action of neuregulin and its receptors, ErbBs, that produces heart failure.

10 In another embodiment, a therapeutic agent which mimics the effects of neuregulin is used to treat or prevent PE, or IGF-1-mediated cardiac muscle cell dysfunction.

15 In an seventh aspect, the present invention consists in a method of determining predisposition to heart disease or heart failure in a subject, the method comprising testing cardiac or related cells of the subject for the ability to express and/or produce normal or adequate levels of neuregulin or its cognate ErbB receptors. The inability to express and/or produce normal or adequate levels of neuregulin being indicative of predisposition to heart disease or heart failure.

20 In a eighth aspect, the present invention consists in the use of neuregulin, neuregulin polypeptide, neuregulin derivatives, or compounds which mimic the activities of neuregulins in the treatment or management of heart disease and heart failure.

25 In a ninth aspect, the present invention consists in the use of neuregulin, neuregulin polypeptide, neuregulin derivatives, or compounds which mimic the activities of neuregulins in the manufacture of a medicament for the treatment or management of heart disease and heart failure.

30 By using primary-cultured myocardial cells as a model system, the present inventor evaluated neuregulin signalling in cardiac myocyte differentiation, maturation and assembly or maintenance of sarcomeric and cytoskeleton structures. To assay the neuregulin effect on cell signalling, embryonic cardiac muscle cells were incubated with recombinantly purified human neuregulin ligand (rhNRG β 2). Neuregulin at 10^{-8} M resulted in sustained activation of MAP kinases for at least 21 hours, whereas only transient activation was observed with a lower concentration (10^{-10} M) of rhNRG β 2. Expression of the Cdk inhibitor, p21^{CIP1}, was enhanced by the 10^{-8} M

⁸M, but not the 10^{-10} M concentration of the ligand. The higher ligand concentration, concomitant with this increase in p21^{CIP1} expression, resulted in a decrease in DNA synthesis, that was associated with terminal differentiation, whereas an increase in DNA synthesis and continued proliferation was observed with the lower dose. Furthermore, when neuregulin was mixed with IGF-1, rhNRG β 2 at either concentrations (10^{-8} M, or 10^{-10} M) did not show a negative effect on the DNA synthesis and significantly blocked IGF-I-stimulated cardiomyocyte proliferation. To further evaluate the NRG-stimulated myocardial cell differentiation, sarcomeric and cytoskeleton structures of cultured neonatal rat cardiac muscle cells were examined by Phalloidin staining and immunofluorescent staining with anti- α -actinin antibody. rhNRG β 2 dramatically improved sarcomeric and cytoskeleton structures, as well as cell-cell adhesions. Such an effect was not found from the cells stimulated with either insulin IGF-1 or PE. When rhNRG β 2 was mixed with either IGF-1 or PE, rhNRG β 2 improved the cell structures. The 10^{-8} M concentration of rhNRG β 2 showed maximal effect on improvements of sarcomeres and cell-cell adhesions. In addition, neuregulin overrode the negative regulation of MHC- α expression mediated by PE stimulation. These findings indicate that NRG function through two distinct pathways: one activated at lower ligand concentrations results in cardiomyocyte growth, whereas the other, activated with higher concentrations, is mediated by sustained activation of the MAP kinase pathway and results in terminal differentiation and maturation.

Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

In order that the present invention may be more clearly understood, preferred forms will be described with reference to the following examples and drawings.

Brief Description of the Drawings

Figure 1. Growth factor-stimulated DNA synthesis. DNA synthesis ($[^3\text{H}]$ thymidine incorporation) by cultured embryonic mouse cardiomyocytes in response to 20 hr of treatment with the indicated concentrations of vehicle (purified Flag-peptide) (open square), recombinant human NRG β 2 (rhNRG β 2) (closed triangle) or insulin-like growth factor-I (IGF-I) (open circle). Data shown are the mean \pm S.E of five determinations with each treatment and at each concentration. All rhNRG β 2 responses are significantly greater than control ($P < 0.001$) except at 10^{-7}M , and the rhNRG β 2 responses to concentration $3 \times 10^{-9}\text{M}$ are significant than the respective IGF-I responses ($P < 0.01$).

Figure 2. NRG-mediated ErbB receptor phosphorylation. (a) Serum-starved cardiomyocytes were stimulated with vehicle (0) or rhNRG β 2 at a concentration of either 10^{-10}M or 10^{-8}M for the times indicated. Phosphorylation of ErbB receptors was then determined as described in Methods using an anti-phosphotyrosine antibody (RC20H). Fold increases in immunoblot intensities are shown, which were normalised for protein load based on the intensities of simultaneously determined immunoblots of ErbB2 shown below the phosphotyrosine species. (b) Phosphorylation of immunoprecipitated ErbB2 (top panel) or ErbB4 (bottom panel) resulting from the stimulation of embryonic cardiomyocytes for 5 min with 10^{-10}M or 10^{-8}M rhNRG β 2. Studies were performed as detailed in Methods and the immunoprecipitated products evaluated by immuno-blotting with anti-phosphotyrosine, anti-ErbB2 or anti-ErbB4 antibodies. Fold changes in immunoblot intensities are shown, which were normalised for protein loading based on the intensities of simultaneously determined immunoblots of ErbB2 or ErbB4 shown below the phosphotyrosine species.

Figure 3. NRG or IGF-I stimulated MAP kinase activation. (a) MAP kinase phosphorylation resulting from embryonic cardiomyocyte stimulation with rhNRG β 2 (10^{-10}M or 10^{-8}M) for the times shown. After treatment with rhNRG β 2, cell extracts were prepared and evaluated for MAP kinase phosphorylation using an anti-phospho MAP kinase antibody, as described in Methods. Fold changes in immunoblot intensities are shown below the phosphotyrosine species. To control for protein loading, cell extracts were simultaneously evaluated for ErbB2 expression by immunoblot analysis using an anti-ErbB2 antibody. (b) MAP kinases catalytic activity was determined

as described in Methods using extracts prepared from cardiomyocytes treated with rhNRG β 2 (10^{-10} M or 10^{-8} M) for the times indicated, and shown as fold increase over the basal level activity of cells which were not stimulated with rhNRG β 2. Values of the fold shown as the means \pm SE of five determinations with each treatment and at each concentration. (c) MAP kinase phosphorylation resulting from IGF-I (10^{-9} M) stimulation of embryonic cardiomyocytes for the times indicated, was determined as in (a).

Figure 4. Effects of NRG on IGF-I stimulated DNA synthesis and MAP kinase phosphorylation. (a) DNA synthesis ($[^3\text{H}]$ thymidine incorporation) was examined in cultured cells stimulated with a maximal concentration of IGF-I (10^{-9} M) in the absence or presence of rhNRG β 2 at concentrations of either 10^{-10} M or 10^{-8} M for 20 hrs. Bars show the mean values of data from five samples \pm 1S.E (error bars). Similar results were obtained from three independent experiments. Significant difference (***, $P < 0.001$) from the control are indicated. (b) Time course of MAPK phosphorylation in embryonic cardiac muscle cells in response to a mixture of 10^{-9} M IGF-I and 10^{-8} M rhNRG β 2 was determined by immunoblotting using a specific anti-phospho-MAPK antibody. ErbB2 expression was evaluated simultaneously to control for protein loading.

Figure 5. NRG-mediated induction of p21^{CIP1} expression. (a) p21^{CIP1} expression in cultured cardiac muscle cells stimulated either with 10^{-10} M or 10^{-8} M rhNRG β 2 in the absence or presence of serum (5% of FBS) for 24 hrs; or (b) with 10^{-10} M or 10^{-8} M IGF-I. After the various treatments, p21^{CIP1} expression was evaluated by immunoblot analysis using an anti-p21^{CIP1} antibody. ErbB2 expression was evaluated simultaneously to control for protein loading. Fold changes in p21^{CIP1} expression, normalised for protein loading, are shown. (c) Effect of the MEK inhibitor (PD98059) (50 μ M) on rhNRG β 2 (either at 10^{-10} M or 10^{-8} M)-mediated stimulation of p21^{CIP1} expression in cultured embryonic cardiac muscle cells in the absence of serum. p21^{CIP1} was detected by immunoblot analysis using an anti-p21^{CIP1} antibody. Fold changes in p21^{CIP1} expression, normalised for protein loading, are shown. (d) Effects of PD98059 on the inhibition of NRG- or IGF-I-activated MAP kinase activities were monitored by a measurement of p42/44 MAP kinase phosphorylation after cells were stimulated with NRG or IGF-I for 5 min. p42/44 MAP kinase phosphorylation was evaluated by immunoblot analysis using anti-phospho-p42/44 or anti-p42/44 MAP kinase

antibodies. The same amount of whole cell extract (20 µg protein) was loaded, and normalised for p42/44 MAP kinase expression, using an anti-p42/44 MAP kinase antibody.

Figure 6. Effects of NRG on cardiac sarcomere assembly and myosin heavy chains expression. (a) E12.5 mouse cardiac muscle cells were cultured in serum-free medium (control) or stimulated with 10^{-10} or 10^{-8} M rhNRGβ2 (NRG) for 48 hrs. Cells were then stained with phalloidin (left panels) or evaluated for anti-α-actinin immunofluorescence (right panels). (b) Sarcomeric myosin heavy chain and α-actin expression in rhNRGβ2-stimulated embryonic mouse cardiac muscle cells were evaluated by immunoblot analysis using an anti-sarcomeric myosin heavy chain antibody (MF20) or an anti-α-actin antibody. The same amount of whole cell extracts (20 µg proteins) was loaded into each lane for SDS-PAGE fractionation.

Modes for Carrying Out the Invention

Utilising an *in vitro* system of cardiac muscle cell differentiation, a role for neuregulin in stimulating the activation of the differentiation response in comparison with two well-defined hormonal and growth factor stimuli, α₁-adrenergic agonists and IGF-1 has been demonstrated. The present inventor has demonstrated that neuregulin differentiation pathways exist within cardiac muscle cells, and that neuregulin polypeptides can activate these pathways. Since cardiac muscle cell differentiation includes the processes of organisation of sarcomeric structures and cell-cell adhesions, the invention, thus, provides a useful method for the treatment and prevention of cardiac muscle cell with disorganisation of the sarcomeric structures and cell-cell adhesions, and the enhancement of heart function in cardiomyopathy, and for identifying polypeptides or compounds which activate cardiac muscle differentiation pathways.

Before the methods of the invention are described, it is to be understood that this invention is not limited to the particular methods described. The terminology used herein is for the purpose of describing particular embodiments only.

As used in this specification, the singular forms "a", "an", and "the" include plural references unless the context clearly dictates otherwise. Thus, for example, references to "neuregulin" or "a neuregulin peptide" includes mixtures of such neuregulins, neuregulin isoforms, and/or neuregulin-like polypeptides. Reference to "the formulation" or "the method" includes one

or more formulations, methods, and/or steps of the type described herein and/or which will become apparent to those persons skilled in the art upon reading this disclosure.

Unless defined otherwise, all technical and scientific terms used
5 herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned herein are
10 incorporated herein by reference for the purpose of disclosing and describing material for which the reference was cited in connection with.

Definitions

"Neuregulin or neuregulin analogs" are molecules that can activate ErbB2/ErbB4 or ErbB2/ErbB3 heterodimer protein tyrosine kinases, such as all
15 neuregulin isoforms, neuregulin EGF domain alone, neuregulin mutants, and any kind of neuregulin-like gene products that also activate the above receptors. The "neuregulin" used in this invention is the following polypeptide which is a fragment of human neuregulin β 2 isoform containing the EGF-like domain, the receptor binding domain.

20 The cDNA sequence:
AGCCATCTTGTAATGTGCGGAGAAGGAGAAAACCTTTCTGTGTGAATGG
AGGGGAGTGCTTCATGGTGAAAGACCTTTCAAACCCCTCGAGATACTTGT
GAGGAGCTGTACCAG (SEQ ID NO:1)

The amino acid sequence encoded by the above DNA sequence:
25 SHLVKCAEKTFCVNGGECFMVKDLSNPSRYLCKCPNEFTGDRCQNYVMASF
YKAEELY (SEQ ID NO:2)

"Cardiac muscle cell differentiation" is a condition characterised by the decrease in DNA synthesis by more than 10%, inhibition of other factor-stimulated DNA synthesis more than 10%, well organised sarcomeric
30 structures and cell-cell adhesions, sustained activation of MAP kinases, and enhanced expression of p21^{CIP1}.

"Organised, or enhanced organisation of sarcomeres or sarcomeric structures" is a condition characterised by the straight array of contractile proteins revealed by immunofluorescent staining of α -actinin in cardiac
35 muscle cells. The straight array of α -actinin proteins in cells can be

distinguished by microscopy and its connected photography as exemplified in Figures of this specification.

"Disorganised or disarray of sarcomeres or sarcomeric structures" is the opposite meaning of the above definitions.

5 "Organised, or enhanced organisation of cytoskeleton structures" is a condition characterised by the straight actin fibers revealed by phalloidin staining of cardiac muscle cells. The straight actin fibers in cells can be distinguished by microscopy and its connected photography as exemplified in Figures of this specification.

10 "Disorganised or disarray of cytoskeleton structures" is the opposite meaning of the above definitions.

"Sustained activation of MAP kinases" is that phosphorylated state of MAP kinases, p42/44, is maintained for at least 21 hr in cells.

15 "Enhanced expression of p21^{CIP1}" is that expression of p21^{CIP1} is increased at least 50% that is maintained for at least 24 hr in cells.

"The treatment of heart diseases" includes all suitable kinds of methods, such as vein injection of the neuregulin polypeptide, and gene therapy methods, in which heart or other cells were forced to contain a gene encoding neuregulin or derivatives for the treatment of heart diseases. For
20 example, Adenovirus or Adeno-Associated-Virus can be used as a carrier to deliver neuregulin gene into infected heart or other cells. The infected cell can then express and secrete neuregulin polypeptide to activate ErbBs on cardiac muscle cells.

"Ventricular muscle cell hypertrophy" is a condition characterised by
25 an increase in the size of individual ventricular muscle cells, the increase in cell size being sufficient to result in a clinical diagnosis of the patient or sufficient as to allow the cells to be determined as larger (e.g., 2-fold or more larger than non-hypertrophic cells). It may be accompanied by accumulation of contractile proteins within the individual cardiac cells and activation of
30 embryonic gene expression.

In vitro and *in vivo* methods for determining the presence of ventricular muscle cell hypertrophy are known. *In vitro* assays for ventricular muscle cell hypertrophy include those methods described herein, e.g., increased cell size and increased expression of atrial natriuretic factor (ANF). Changes in
35 cell size are used in a scoring system to determine the extent of hypertrophy. These changes can be viewed with an inverted phase microscope, and the

degree of hypertrophy scored with an arbitrary scale of 7 to 0, with 7 being fully hypertrophied cells, and 3 being non-stimulated cells. The 3 and 7 states may be seen in Simpson et al. (1982) Circulation Res. 51: 787-801, Figure 2, A and B, respectively. The correlation between hypertrophy score and cell surface area (μm^2) has been determined to be linear (correlation coefficient = 0.99). In phenylephrine-induced hypertrophy, non-exposed (normal) cells have a hypertrophy score of 3 and a surface area/cell of $581\mu\text{m}^2$ and fully hypertrophied cells have a hypertrophy score of 7 and a surface area/cell of $1811\mu\text{m}^2$, or approximately 200% of normal. Cells with a hypertrophy score of 4 have a surface area/cell of $771\mu\text{m}^2$, or approximately 30% greater size than non-exposed cells; cells with a hypertrophy score of 5 have a surface area/cell of $1109\mu\text{m}^2$, or approximately 90% greater size than non-exposed cells; and cells with a hypertrophy score of 6 have a surface area/cell of $1366\mu\text{m}^2$, or approximately 135% greater size than non-exposed cells. The presence of ventricular muscle cell hypertrophy preferably includes cells exhibiting an increased size of about 15% (hypertrophy score 3.5) or more. Inducers of hypertrophy vary in their ability to induce a maximal hypertrophic response as scored by the above-described assay. For example, the maximal increase in cell size induced by endothelin is approximately a hypertrophy score of 5.

"Suppression" of ventricular muscle cell hypertrophy means a reduction in one of the parameters indicating hypertrophy relative to the hypertrophic condition, or a prevention of an increase in one of the parameters indicating hypertrophy relative to the normal condition. For example, suppression of ventricular muscle cell hypertrophy can be measured as a reduction in cell size relative to the hypertrophic condition. Suppression of ventricular muscle cell hypertrophy means a decrease of cell size of 10% or greater relative to that observed in the hypertrophic condition. More preferably, suppression of hypertrophy means a decrease in cell size of 30% or greater; most preferably, suppression of hypertrophy means a decrease of cell size of 50% or more. Relative to the hypertrophy score assay when phenylephrine is used as the inducing agent, these decreases would correlate with hypertrophy scores of about 6.5 or less, 5.0-5.5, and 4.0-5.0, respectively. When a different agent is used as the inducing agent, suppression is measure relative to the maximum cell size (or hypertrophic score) measured in the presence of that inducer.

Prevention of ventricular muscle cell hypertrophy is determined by preventing an increase in cell size relative to normal cells, in the presence of a concentration of inducer sufficient to fully induce hypertrophy. For example, prevention of hypertrophy means a cell size increase less than 200% greater than non-induced cells in the presence of maximally-stimulating concentration of inducer. More preferably, prevention of hypertrophy means a cell size increase less than 135% greater than non-induced cells; and most preferably, prevention of hypertrophy means a cell size increase less than 90% greater than non-induced cells. Relative to the hypertrophy score assay when phenylephrine is used as the inducing agent, prevention of hypertrophy in the presence of a maximally-stimulating concentration of phenylephrine means a hypertrophic score of about 6.0-6.5, 5.0-5.5, and 4.0-4.5, respectively.

In vivo determination of hypertrophy include measurement of cardiovascular parameters such as blood pressure, heart rate, systemic vascular resistance, contractility, force of heart beat, concentric or dilated hypertrophy, left ventricular systolic pressure, left ventricular mean pressure, left ventricular end-diastolic pressure, cardiac output, stroke index, histological parameters, and ventricular size and wall thickness. Animal models available for determination of development and suppression of ventricular muscle cell hypertrophy *in vivo* include the pressure-overload mouse model, RV murine dysfunctional model, transgenic mouse model, and post-myocardial infarction rat model. Medical methods for assessing the presence, development, and suppression of ventricular muscle cell hypertrophy in human patients are known, and include, for example, measurements of diastolic and systolic parameters, estimates of ventricular mass, and pulmonary vein flows.

The terms "treatment", "treating" and the like are used herein to generally mean obtaining a desired pharmacological and/or physiological effect. The effect may be prophylactic in terms of completely or partially preventing a disease or symptom thereof and/or may be therapeutic in terms of a partial or complete cure for a disease and/or adverse effect attributable to the disease. "Treatment" as used herein covers any treatment of a disease in a mammal, particularly a human, and includes:

preventing the disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it;

inhibiting the disease, i.e., arresting its development; or
relieving the disease, i.e., causing regression of the disease.

The invention is directed to treating patients with or at risk for
development of heart disease and related conditions, e.g., heart failure. More
5 specifically, "treatment" is intended to mean providing a therapeutically
detectable and beneficial effect on a patient suffering from heart disease.

By the term "heart failure" is meant an abnormality of cardiac function
where the heart does not pump blood at the rate needed for the requirements
of metabolising tissues. Heart failure includes a wide range of disease states
10 such as congestive heart failure, myocardial infarction, tachyarrhythmia,
familial hypertrophic cardiomyopathy, ischaemic heart disease, idiopathic
dilated cardiomyopathy, and myocarditis. The heart failure can be caused by
any number of factors, including ischaemic, congenital, rheumatic, or
idiopathic forms. Chronic cardiac hypertrophy is a significantly diseased
15 state which is a precursor to congestive heart failure and cardiac arrest.

"Treatment" refers to both therapeutic treatment and prophylactic or
preventative measures, wherein the object is to prevent or slow down (lessen)
hypertrophy. Those in need of treatment include those already with the
disorder as well as those prone to have the disorder or those in which the
20 disorder is to be prevented. The hypertrophy may be from any cause which
is responsive to retinoic acid, including congenital, viral, idiopathic,
cardiotrophic, or myotrophic causes, or as a result of ischaemia or ischaemic
insults such as myocardial infarction. Typically, the treatment is performed
to stop or slow the progression of hypertrophy, especially after heart damage,
25 such as from ischaemia, has occurred. Preferably, for treatment of
myocardial infarctions, the agent(s) is given immediately after the myocardial
infarction, to prevent or lessen hypertrophy.

The terms "synergistic," "synergistic effect" and like are used herein to
describe improved treatment effects obtained by combining one or more
30 therapeutic agents with one or more retinoic acid compounds. Although a
synergistic effect in some fields is meant an effect which is more than
additive (e.g., $1+1=3$), in the field of medical therapy an additive ($1+1=2$) or
less than additive ($1+1=1.6$) effect may be synergistic. For example, if each
of two drugs were to inhibit the development of ventricular muscle cell
35 hypertrophy by 50% if given individually, it would not be expected that the
two drugs would be combined to completely stop the development of

ventricular muscle cell hypertrophy. In many instances, due to unacceptable side effects, the two drugs cannot be administered together. In other instances, the drugs counteract each other and slow the development of ventricular muscle cell hypertrophy by less than 50% when administered together. Thus, a synergistic effect is said to be obtained if the two drugs slow the development of ventricular muscle cell hypertrophy by more than 50% while not causing an unacceptable increase in adverse side effects.

MATERIALS AND METHODS

Reagents and Antibodies

The following antibodies and reagents were used: IGF (*Boehringer*); collagenase (*Worthington*); pancreatin (*Gibco BRL*); MEK1 (MAPKK) inhibitor (PD98059) (*New England*); [methyl-³H]thymidine (*Amersham*); monoclonal anti-erbB2 antibody (*Novocastra*); monoclonal IgG_{2b} p21^{CIP1} (F-5) (*Santa Cruz*); monoclonal anti-phospho-tyrosine horse radish peroxidase (HRPO)-conjugated antibody, RC20 (*Transduction Laboratories*); monoclonal anti- α -sarcomeric actin antibody (clone 5c5), HRPO-conjugated anti-rabbit Ig, and anti-mouse Ig (*Sigma*); PhosphoPlus® p44/42 MAP kinase (Thr202/Tyr204) antibody kit (*New England*); anti-FLAG® M1 affinity gel and anti-FLAG M2 monoclonal antibody (*Eastman Kodak*) mAb MF20 to sarcomeric myosin heavy chain (kindly provided by R. P. Harvey, Victor Chang Cardiac Research Institute); anti-sarcomeric α -actin antibody (*Sigma*).

Recombinant human NRG β 2 expression and purification

A cDNA encoding the EGF-like domain of human NRG β 2 isoform (rhNRG β 2), residues 177-237, was inserted into the pFLAG1 expression vector (*IBI*) (a gift from Dr. Rodney J. Fiddes, Co-operative Research Centre for Biopharmaceutical Research, Australia). rhNRG β 2 with a FLAG-peptide attached at its N-terminus, was expressed in the periplasmic space of *E. coli* DH5 α , and purified by affinity chromatography using anti-FLAG M1 monoclonal antibody according to the manufacturer's instructions. The purity of rhNRG β 2 was more than 90% as evidenced by SDS-PAGE separation and Coomassie Blue staining of purified protein samples. The concentration of purified proteins was determined using a Bio-Rad protein assay kit. Activity of the purified proteins was assayed by stimulation of MCF-7 breast cancer cell ErbB receptors with various ligand doses. This revealed increased ErbB receptor phosphorylation with increasing ligand concentration (10^{-12} M to 10^{-8} M).

Primary cultures of mouse cardiac myocytes

Mouse embryos (E11.5-12.5) were used to prepare primary cardiac myocytes. Heart tissue was isolated aseptically from embryos. Myocardial cells were isolated by collagenase digestion and separated from non-cardiomyocytes by preattachments on culture dishes that was performed three times. Cells were then cultured as described previously. Using this method, it was routinely possible to obtain primary cultures with >90% myocytes.

ErbB and MAP kinase phosphorylation, and MAP kinase activity

Embryonic myocardial cells were cultured in serum-free medium for at least 24 hrs and then stimulated with rhNRG β 2 or IGF-I for various times. Stimulation was terminated by washing cells rapidly with cold PBS. To block the MAP kinase activation, the MEK inhibitor, PD98059, was added to the medium 30 mins prior to the administration of rhNRG β 2 or IGF-I. Cells were then harvested as previously described for Western blot analysis with HRPO-conjugated monoclonal antibody RC20H (1:2,000) for detection of phosphorylated ErbB receptors, or a phospho-specific p42/p44 MAP kinase antibody (dilution ratio 1:1,000) for detection of phosphorylated MAP kinases. The same amount of cell extract protein was loaded into each lane and separated by SDS-PAGE. Immunoblotting with an anti-ErbB receptor or anti-p42/44 MAP kinase antibodies was also used to normalise for protein loading. MAP-kinase (p42/p44) activity was measured using a p42/44 MAP kinase enzyme assay kit (RPN84; Amersham, Bucks., U.K.) according to the manufacturer's instructions.

Detection of p21^{CIP1} protein

Embryonic myocardial cells cultured in serum-free or 5% FBS medium were stimulated with various concentrations of rhNRG β 2 with or without the MEK inhibitor, PD98059, for 24 or 48 hrs, harvested as described above and subjected to immunoblot analysis using an anti-p21^{CIP1} antibody (1:100). The same amount of protein was loaded into each well of a SDS polyacrylamide gel. After immunoblotting, the membrane was stripped and probed further with an antibody to the ErbB2 receptor for normalisation of protein loading.

Thymidine Incorporation

Embryonic myocardial cells were cultured with rhNRG β 2 or IGF-I containing serum-free DMEM for 20 hrs. [methyl -³H] Thymidine (0.5 μ Ci/well) was added and cells were then cultured for a further 12 hrs.

After rinsing twice with cold PBS, once with ice-cold 10% trichloroacetic acid, and then five times with ice-cold PBS, the cells were dissolved in 100 μ l of 1% SDS, and counted in a liquid scintillation counter.

Immunofluorescent and phalloidin staining

5 Myocardial cells were plated in 2-well Novex plates (*Nunc*), and cultured with or without rhNRG β 2 in serum-free DMEM medium for 24-48 hour. After rinsing the cells with PBS, they were fixed with 4% paraformaldehyde and 0.1% Triton X-100 at room temperature for 30 minutes. The fixed cells were then blocked with 5% skim milk in PBS for 1
10 hr, followed by incubation with an anti- α -actinin monoclonal antibody (*Sigma*), for 45 minutes at room temperature. After washing, anti-mouse IgG conjugated with FITC (*Sigma*) was added and the cells were incubated for another half hour. For phalloidin staining, cells were fixed with 4% formadehyde for 1 hr, washed, and stained with phalloidin buffer (100 μ l PBS,
15 10ul rhodamine phalloidin (6.6 μ M in MeOH)) for 1 hr. After PBS washing, cells were mounted with 1% *p*-phenylenediamine (1mg/ml, *Sigma*) in glycerol, and then covered and sealed. Cells were examined using a UV fluorescent microscope and photographed with a 40x power objective.

20 All of the above assays were repeated at least three times for each experiments. Data for DNA synthesis and MAP kinase activity are presented as the mean \pm S.E of five replicate samples. Statistical significance was determined by ANOVA using the SAS statistical package with $P < 0.05$ being considered significant. Immunoblots were quantitated by densitometry analysis with the intensity of the evaluated protein bands being shown below
25 the blots as the fold changes over control (see Figures).

RESULTS

NRG regulates embryonic myocardial cell DNA synthesis

DNA synthesis in primary embryonic mouse cardiomyocytes (E11.5-12.5) was evaluated to investigate their growth response to NRG following
30 stimulation with rhNRG β 2. As shown in Figure 1, rhNRG β 2 at a concentration of 10^{-10} M produced an approximately 2-fold increase in the DNA synthesis. However, DNA synthesis decreased with ligand concentrations $> 10^{-10}$ M. In contrast to the response to rhNRG β 2, myocardial cells showed only a proliferative response to recombinant human insulin-like
35 growth factor I (IGF-I), in concentrations ranging from 10^{-11} M to 10^{-7} M. Inhibition of DNA synthesis by the higher concentrations of NRG was not

due to *E.coli* proteins contaminating the bacterially-expressed rhNRG β 2, since proteins purified from bacteria transformed with FLAG-vector alone did not inhibit DNA synthesis. Moreover, to avoid possible effects of *E.coli* proteins, both commercially obtained IGF-I and purified rhNRG β 2 were dissolved or diluted with anti-FLAG-protein preparations (10^{-8} M of FLAG peptide). These reagents showed identical activities to those prepared with PBS in stimulating myocardial cell DNA synthesis.

NRG activates embryonic myocardial cell ErbB receptors

Of the four members of the ErbB receptor family (ErbB1-4), ErbB2 and ErbB4 are most abundantly expressed in cardiac myocytes. Phosphorylation of ErbB2 and ErbB4 receptors was evaluated by Western blot analysis of cell lysates, following stimulation with either 10^{-8} M or 10^{-10} M rhNRG β 2. As shown in Figure 2a, a higher level of phosphorylated 180-185kDa proteins corresponding to ErbB2/ErbB4 receptors, was evident with the higher concentration of NRG. The levels of phosphorylation gradually decreased with time. The concentration dependence of p180-185 protein phosphorylation corresponded to that for the decrease in DNA synthesis with rhNRG β 2 treatment (Fig. 1). ErbB2 and ErbB4 receptors were also immunoprecipitated using anti-ErbB2 or ErbB4 antibodies, and examined by Western blotting with anti-phospho-tyrosine antibodies. As shown in Figure 2b, phosphorylation of both receptors was dependent on rhNRG β 2 concentrations. Although ErbB2 and ErbB4 phosphorylation levels differed slightly between experiments, the relative phosphorylation difference between high and low concentrations of rhNRG β 2 persisted.

NRG concentration-dependent activation of MAP kinases

Activation of the ErbB receptor family initiates a cascade of molecular interactions, ultimately resulting in the stimulation of MAP kinases. The duration of MAP kinase activation is critical for cell-fate decisions. Therefore, the present inventor investigated the time course of MAP kinase phosphorylation after either 10^{-8} M or 10^{-10} M rhNRG β 2 treatment, using a specific-phospho-MAP kinase antibody, which recognises phosphorylated p42/p44 MAP kinases. As shown in Figure 3a, phosphorylation of p42/p44 MAP kinases was sustained for at least 21 hours with the higher dose of rhNRG β 2. MAP kinase activation was transient at the lower ligand concentration, and fell to the basal level in less than three hours. As shown in Figure 3b, MAP kinase catalytic activity paralleled these changes in

phosphorylation. Thus, MAP kinase activity was sustained for at least 21 hours in cells stimulated with 10^{-8} M rhNRG β 2, but was only transient in cells treated with 10^{-10} M rhNRG β 2. In contrast to these NRG responses, MAP kinase phosphorylation was transient both with low (10^{-9} M) (Fig. 3c) and with high concentrations (10^{-8} M or 10^{-7} M) of IGF-I.

Effect of NRG on IGF-I-stimulated myocardial cell proliferation

Since myocardial cells are exposed to multiple peptide hormones and growth factors *in vivo*, the present inventor investigated if the growth inhibitory effects of a high concentration of NRG could oppose the proliferative response of other growth factors. This was achieved by evaluating the effects of both rhNRG β 2 and IGF-I on cardiac myocyte DNA synthesis. As shown in Fig. 4a, a 10^{-10} M concentration of NRG had little effect on IGF-I (10^{-9} M)-stimulated DNA synthesis. However, the 10^{-8} M concentration significantly blocked the IGF-I response. This indicated that a specific intracellular pathway was activated by the higher concentration of NRG. Interestingly, no additive effect was observed when both IGF-I and the lower concentration of NRG were applied to cells, indicating that the 10^{-9} M concentration of IGF-I may already be maximal. That the pathway(s) activated by the higher concentration of NRG may be dominant over that activated by IGF-I was further supported by the observation that the combination of IGF-I (10^{-9} M) and rhNRG β 2 (10^{-8} M) resulted in sustained MAP kinase phosphorylation (compare Fig. 4b and Fig. 3c)

NRG and p21^{CIP1} expression

Since sustained activation of MAP kinase is directly related to the expression of p21^{CIP1} in other types of cells,³¹ and accumulation of p21^{CIP1} leads to cell cycle arrest at the G1 phase,^{32, 33} it was asked if the sustained activation of MAP kinases leads to a higher level of p21^{CIP1} expression in embryonic cardiac muscle cells. As shown in Fig. 5a, an increase in p21^{CIP1} expression was observed only with the higher concentration of rhNRG β 2. This effect on p21^{CIP1} expression was independent of the cell culture conditions used, since similar effects were observed with both serum-free and serum-containing culture medium. Enhanced p21^{CIP1} expression with 10^{-8} M rhNRG β 2 was sustained for at least 24 hours (a 48 hour incubation of cells with rhNRG β 2 results in an identical expression of p21^{CIP1}), and thus, may be critical for the inhibition of DNA synthesis in cardiac muscle cells treated with the high concentration of NRG. As shown in Fig. 5b, IGF-I did not

stimulate p21^{CIP1} expression. To evaluate if the p21^{CIP1} response involves MAP kinase activation, cardiomyocytes were treated with the specific MAP kinase kinase (MEK1) inhibitor (PD98059). Both in the presence or absence of serum, PD98059 blocked the increase in p21^{CIP1} expression induced by 10⁻⁸M rhNRGβ2 (Fig. 5c), as well as the increase in p42/44 MAP kinase phosphorylation (Fig. 5d).

NRG sarcomeric structure and MHC expression

To examine if NRG also affects embryonic myocardial cell structure and function, the effects of NRG on cardiomyocyte cytoskeletal and sarcomeric structures were evaluated. As shown in Fig. 6a, rhNRGβ2 (10⁻⁸M) stimulated both sarcomeric actin reorganisation (phalloidin staining) and cardiac contractile unit assembly (staining of α-actinin in Z-bands). In contrast, effects of 10⁻¹⁰M rhNRGβ2 were much less evident (Fig. 6a). A role for NRG in the regulation of myocardial cell function was also evident by the observation that rhNRGβ2 enhanced expression of sarcomeric myosin heavy chains, while sarcomeric actin expression remained unchanged (Fig. 6b). Moreover, the effects of rhNRGβ2 on cardiomyocytes were also sensitive to MEK1 inhibition by PD98059.

DISCUSSION

Evidence provided indicates that ligand (NRG) concentration is an important factor in determining either the transient or sustained activation states of MAP kinases. The latter results in increased expression level of the Cdk inhibitor, p21^{CIP1}, and is associated with decreased DNA synthesis in embryonic myocardial cells. This finding provides clear support that the ligand gradient may decide cell fate in cell differentiation and embryo development, and further furnishes molecular insights on how intracellular signalling pathways distinguish the signal strength based on ligand concentrations.

The importance of ligand concentration in cell differentiation has been suspected for some time based on the following observations:

- i) embryo developmental patterning is associated with a ligand gradient;
- ii) ligand concentration is critical for cell differentiation *in vitro*, and
- iii) overexpression of receptors in cells changes their fate in response to ligand stimulation.

Taking these observations into consideration, NRG concentration-dependent MAP kinase activation in embryonic myocardial cells establishes

a model for further delineating the mechanisms of erbB receptor-coupled cell signalling in reaction to changes in ligand concentration.

The notion that NRG is a myocardial cell differentiation factor is supported by the finding that NRG induces expression of p21^{CIP1} in embryonic myocardial cells. As p21^{CIP1} is well documented to be an inhibitor of Cdk, which promotes entry from the G1 to the S phase of the cell cycle, increased expression of this protein in myocardial cells could be critical for the initiation of terminal differentiation. This is also supported by previous findings that p21^{CIP1} expression increases *in vivo* with the onset of myocardial cell terminal differentiation (Parker et al. (1995) Science 267:1024-1027), as well as with skeletal muscle cell differentiation (Dias et al. (1994) Semin. Diagn Pathol. 11:3-14). In the latter process, increased p21^{CIP1} expression eventually results in an exit from the cell cycle and differentiation. Since increase in p21^{CIP1} expression occurs prior to that of other cell cycle regulators, it is used as an early marker for skeletal muscle differentiation. As demonstrated here, expression of p21^{CIP1} is concomitant with the decrease in DNA synthesis in NRG-stimulated myocardial cells, suggesting the physiological role of NRG-stimulated p21^{CIP1} expression in these cells. Furthermore, the inhibition of both MAP kinases and p21^{CIP1} by the ERK kinases inhibitor assessed that NRG-stimulated p21^{CIP1} expression is a direct result of activation of MAP kinases.

The sustained activation of MAP kinases is required for induction of p21^{CIP1} constitutive expression in cultured myocardial cells, whereas transient MAP kinase activation results in temporal expression of p21^{CIP1}. The latter is presumably insufficient to regulate the Cdk activity, since p21^{CIP1} will be quickly degraded and constitutive expression is essential for blocking the cyclin/Cdk complex. In PC12 cells, sustained activation of the MAP kinase pathway is confined to a response to specific signals from NGF receptors. The sustained activation of MAP kinases causes PC12 cell differentiation becoming neuronal cells. This pathway in cardiac myocytes, however, is able to differentially respond to NRG concentration-based signal strength.

Further evidence support that NRG is a differentiation factor is that NRG stimulate assembly of sarcomeric and cytoskeleton structures, which occur as myocardial progenitor cells differentiate to cardiac muscle cells. Previous observation also indicated that more differentiated cells have more

Two very important features of heart failure associated with cardiomyopathy in patients are disarrays of myofibers and sarcomeres. The former is the loose of the cell-cell adhesion and the latter is the loose of the sarcomere organisation. These pathological conditions widely exist from congestive heart failure to dilated cardiomyopathy and severely affect heart function. Currently no treatment is target on the assembly of cell-cell adhesion and sarcomere structures. NRG clearly plays a role in the process of the assembly and maintenance of cell-cell adhesion and sarcomeric structures. That NRG stimulates myocardial cell differentiation and the assembly of sarcomeric structures indicates that cardiac muscle cell differentiation is associated with its cell structure remodelling. Such a conclusion is consistent with general observation from heart muscle cell differentiation during heart development: differentiated muscle cells always contain well organised sarcomeres.

i) NRG stimulates sustained activation of MAP kinases;

- ii) NRG enhances p21^{CIP1} expression;

ii) NRG inhibits IGF-1-stimulated DNA synthesis; and

iv) NRG stimulates the myocardial cell assembly of sarcomeric and cytoskeleton structures.

v) NRG stimulates expression of the adult-type MHC gene.

THERAPEUTIC USE

The present invention provides methods for treating or preventing heart failure or cardiac muscle cell hypertrophy in a mammal by providing an effective amount of a neuregulin. Preferably, the mammal is a human patient suffering from or at risk of developing heart failure.

The present invention is useful in preventing heart failure and cardiomyopathy in patients being treated with a drug which cause cardiac hypertrophy or congestive heart failure, e.g., fludrocortisone acetate or herceptin. In the method of the invention, a neuregulin polypeptide can be given prior to, simultaneously with, or subsequent to a drug which causes cardiac diseases.

In the therapeutic method of the invention, a neuregulin polypeptide is administered to a human patient chronically or acutely, for example by injection into the patient's vein. Optionally, neuregulin is administered chronically in combination with an effective amount of a compound that acts to suppress a different hypertrophy induction pathway than a neuregulin. Additional optional components include a cardiotropic inhibitor such as a Ct-1 antagonist, an ACE inhibitor, such as captopril, and/or human growth hormone and/or IGF-I in the case of congestive heart failure, or with another anti-hypertrophic, myocardiotropic factor, anti-arrhythmic, or inotropic factor in the case of other types of heart failure or cardiac disorder.

The present invention can be combined with current therapeutic approaches for treatment of heart failure, e.g., with ACE inhibitor treatment. ACE inhibitors are angiotensin-converting enzyme inhibiting drugs which prevent the conversion of angiotensin I to angiotensin II. The ACE inhibitors may be beneficial in congestive heart failure by reducing systemic vascular resistance and relieving circulatory congestion. ACE inhibitors include drugs designated by the trademarks Accupril® (quinapril), Altace® (ramipril), Capoten® (captopril), Lotensin® (benazepril), Monopril® (fosinopril), Prinivil® (lisinopril), Vasotec® (enalapril), and Zestril® (lisinopril).

The present invention can be combined with the administration of drug therapies for the treatment of heart diseases such as hypertension. For example, a neuregulin polypeptide can be administered with endothelin receptor antagonists, for example, and antibody to the endothelin receptor, and peptide or other such small molecule antagonists; β -adrenoreceptor antagonists such as carvedilol; α_1 -adrenoreceptor antagonists; anti-oxidants;

compounds having multiple activities (e.g., β -blocker/ α -blocker/anti-oxidant); carvedilol-like compounds or combinations of compounds providing multiple functions found in carvedilol; growth hormone, etc.

5 Neuregulin agonists alone or in combination with other hypertrophy suppressor pathway agonists or with molecules that antagonise known hypertrophy induction pathways, are useful as drugs for *in vivo* treatment of mammals experiencing heart failure, so as to prevent or lessen heart failure effects.

10 Therapeutic formulations of agonist(s) for treating heart disorders are prepared for storage by mixing the agonist(s) having the desired degree of purity with optional physiologically acceptable carriers, excipients, or stabilisers (Remington's Pharmaceutical Sciences, 16th edition, Oslo, A., Ed., 1980), in the form of lyophilised cake or aqueous solutions. Acceptable carriers, excipients, or stabilisers are non-toxic to recipients at the dosages
15 and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates
20 including glucose, mannose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counter ions such as sodium; and/or non-ionic surfactants such as Tween, Pluronic, or polyethylene glycol (PEG). The antagonist(s) are also suitably linked to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol, polypropylene glycol, or polyalkylenes, in the manner set forth in US Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337. The amount of carrier used in a formulation may range from about 1 to 99%, preferably from about 80 to 99%, optimally between 90 and 99% by weight.

30 The agonist(s) to be used for *in vivo* administration should be sterile. This is readily accomplished by methods known in the art, for example, by filtration through sterile filtration membranes, prior to or following lyophilisation and reconstitution. The agonist(s) ordinarily will be stored in lyophilised form or in solution.

35 Therapeutic agonist compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial

having a stopper pierceable by a hypodermic injection needle. The agonist(s) administration is in a chronic fashion only, for example, one of the following routes: injection or infusion by intravenous, intraperitoneal, intracerebral, intramuscular, intraocular, intraarterial, or intralesional routes, orally or using sustained-release systems as noted below. Agonist(s) are administered continuously by infusion or by periodic bolus injection if the clearance rate is sufficiently slow, or by administration into the blood stream or lymph. The preferred administration mode is targeted to the heart, so as to direct the molecule to the source and minimise side-effects of the agonists.

Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the protein, which matrices are in form of shaped articles, e.g., films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (e.g., poly(2-hydroxyethyl-methacrylate) as described by Langer et al. (1981) J. Biomed. Mater. Res. 15: 167-277 and Langer (1982) Chem. Tech. 12: 98-105, or poly(vinyl alcohol)), polylactides (US Patent No 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma ethyl-L-glutamate (Sidman et al. (1983) Biopolymers 22: 547-556), non-degradable ethylene-vinyl acetate (Langer et al. (1981) supra) degradable lactic acid-glycolic acid copolymers such as the Lupron Depot™ (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid (EP 133,988).

The agonist(s) also may be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerisation (for example, hydroxymethylcellulose or gelatin-microcapsules and poly-[methylmethacrylate] microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules), or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences, *supra*.

While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release molecules for shorter time periods. When encapsulated molecules remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37°C, resulting in a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for

Sustained-release agonist(s) compositions also include liposomally entrapped agonists(s). Liposomes containing agonists(s) are prepared by methods known *per se*: DE 3,218,121; Epstein et al. (1985) Proc. Natl. Acad. Sci. USA 82: 3688-3692; Hwang et al. (1980) Proc. Natl. Acad. Sci. USA 77: 4030-4034; EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese patent application 83-118008; US Patent Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily the liposomes are of the small (about 200-800 Å) unilamellar type in which the lipid content is greater than about 30 mol% cholesterol, the selected proportion being adjusted for the optimal agonist therapy. A specific example of suitable sustained-release formulation is in EP 647,449.

15 An effective amount of NRG to be employed therapeutically will depend, for example, upon the therapeutic objectives, the route of administration, and the condition of the patient. Accordingly, it will usually be necessary for the clinician to titrate the dosage and modify the route of administration as required to obtain the optimal therapeutic effect.

NRG optionally is combined with or administered in concert with other agents for treating congestive heart failure, including ACE inhibitors, CT-1 inhibitors, human growth hormone, and/or IGF-I. The effective amounts of such agents, if employed, will be at the clinician's discretion. Dosage administration and adjustment are determined by methods known to those skilled in the art to achieve the best management of congestive heart failure and ideally takes into account use of diuretics or digitalis, and conditions such as hypotension and renal impairment. The dose will additionally depend on such factors as the type of drug used and the specific patient being treated. Typically the amount employed will be the same dose as that used if the drug were to be administered without agonist; however, lower doses may be employed depending on such factors as the presence of side-effects, the condition being treated, the type of patient, and the type of agonists and drug, provided the total amount of agents provides an effective dose for the condition being treated.

Thus, for example, in the case of ACE inhibitors, a test dose of
35 enalapril is 5 mg, which is then increased up to 10-20 mg per day, once a
day, as the patient tolerates it. As another example, captopril is initially

administered orally to human patients in a test dose of 6.25 mg and the dose is then escalated, as the patient tolerates it to 25 mg twice per day (BID) or three times per day (TID) and may be titrated to 50 mg BID or TID. Tolerance level is estimated by determining whether decrease in blood pressure is
5 accompanied by signs of hypotension. If indicated, the dose may be increased up to 100 mg BID or TID. Captopril is produced for administration as the active ingredient, in combination with hydrochlorothiazide, and as a pH stabilised core having an enteric or delayed release coating which protects captopril until it reaches the colon. Captopril is available for
10 administration in tablet or capsule form. A discussion of the dosage. Administration, indications and contraindications associated with captopril and other ACE inhibitors can be found in the Physicians Desk Reference, Medical Economics Data Production Co., Montvale, NJ. 2314-2320 (1994).

In an example of an injectable therapeutic composition of neuregulin,
15 the formulation contains 1% neuregulin and 99% saline, where neuregulin is a polypeptide thereof. In another example of an injectable therapeutic composition of neuregulin, the formulation contains 5% of the neuregulin polypeptide, 1% ACE inhibitor captopril, and 94% saline.

It will be appreciated by persons skilled in the art that numerous
20 variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

CLAIMS:

1. A method of causing cardiomyocyte growth and/or differentiation, the method comprising exposing a cardiomyocyte to neuregulin (NRG) thereby activating the MAP kinase pathway in the cardiomyocyte and causing growth
5 and/or differentiation of the cardiomyocyte.
2. A method of inducing remodelling of cardiac muscle cell sarcomeric and cytoskeleton structures, or cell-cell adhesions, the method comprising treating cardiac muscle cells with neuregulin thereby activating the MAP
10 kinase pathway in the cells and causing remodelling of the cell structures or the cell-cell adhesions.
3. The method according to claim 1 or 2 wherein neuregulin is provided directly to the cardiac cell or provided indirectly by causing neuregulin to be produced in other cells by inducing expression of the gene(s) involved in
neuregulin production.
- 15 4. The method according to claim 1 or 2 wherein neuregulin production is in the cardiac muscle cell to which the method is directed in an autocrine manner or produced by some other cell and released in a paracrine manner.
5. The method according to any one of claims 1 to 4 wherein function of a normal or diseased heart is improved by the treatment with neuregulin.
- 20 6. A method of identifying polypeptides or compounds which stimulate cardiac muscle cell differentiation, the method comprising contacting the cardiac muscle with a test polypeptide or compound in the presence of an inducer of cardiac muscle cell proliferation in the form of neuregulin, and measuring the development of cardiac muscle cell differentiation.
- 25 7. The method according to claim 6 wherein the differentiation of cardiac muscle cells is measured in cells exposed to neuregulin or other test polypeptides, or to a mixture of neuregulin with a test polypeptide.
8. The method according to claim 6 wherein differentiation of cardiac
30 muscle cell is measured by a test selected from the group consisting of calculation of increases or decreases in DNA synthesis, analysis of the time-course of phosphorylation of MAP kinases in cardiac muscle cells, evaluation of the expression of cell cycle inhibitor, p21^{CIP1}, phenotypic organisation of contractile units, accumulation of contractile units, phenotypic alteration of cytoskeleton actin fibers, and phenotype of cell-cell adhesions.

9. The method according to claim 6 wherein cells are incubated with different concentrations of various peptides or compounds and the effect of the test peptide or compound in different concentrations on cardiac muscle cell differentiation is measured.
- 5 10. The method according to claim 6 wherein cells are incubated with IGF-1, with and without the test polypeptide or compound, and the ability of the test polypeptide or compound to inhibit IGF-1-mediated cardiac muscle cell DNA synthesis, assembly of sarcomeric structures and cell-cell adhesions are measured.
- 10 11. The method according to claim 6 wherein the cells are incubated with phenylephrine (PE) with and without the test polypeptide or compound, and the ability of the test polypeptide or compound to augment PE-mediated cardiac muscle cell differentiation is determined.
- 15 12. The method according to claim 6 wherein the test polypeptide stimulates cardiac muscle cell differentiation and stimulates the assembly of sarcomeres thus enhancing heart function by activating neuregulin-specific receptors ErbB2, ERbB3 and ErbB4.
- 20 13. A method of identifying polypeptides or compounds which inhibit neuregulin stimulation of ventricular muscle cell differentiation, the method comprising contacting the ventricular muscle cell with the test polypeptide or compound in the presence neuregulin and measuring any inhibition of neuregulin stimulation of the ventricular muscle cell.
- 25 14. The method according to claim 13 wherein the compound inhibits neuregulin stimulation of ventricular muscle cell differentiation by blocking, suppressing, reversing, or antagonising the action of neuregulin.
- 30 15. The method according to claim 14 wherein the measurement is by detecting DNA synthesis of ventricular muscle cells.
- 35 16. A therapeutic method of treating or preventing disassociation of cardiac muscle cell-cell adhesion and/or the disarray of sarcomeric structures in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a neuregulin or its derivatives.
17. The method according to claim 16 wherein the therapeutic method is directed to treating heart failure resulting from disassociation of cardiac muscle cell-cell adhesion and/or the disarray of sarcomeric structures in the mammal.

18. A method of preventing or lowering the incidence of heart disease in a mammal, the method comprising preventing or lowering the interference or effects of polypeptides or compounds on the action of neuregulin and its receptors, ErbBs, that produces heart failure.
- 5 19. Use of therapeutic agent which mimics the effects of neuregulin to treat or prevent PE, or IGF-1-mediated cardiac muscle cell dysfunction.
20. A method of determining predisposition to heart disease or heart failure in a subject, the method comprising testing cardiac or related muscle cells of the subject for the ability to express and/or produce normal or
10 adequate levels of neuregulin or its cognate ErbB receptors.
21. The method according to claim 20 wherein the inability to express and/or produce normal or adequate levels of neuregulin being indicative of predisposition to heart disease or heart failure.
22. Use of neuregulin, neuregulin polypeptide, neuregulin derivatives, or
15 compounds which mimic the activities of neuregulins in the treatment or management of heart disease and heart failure in a mammal.
23. The use according to claim 22 wherein the concentration of neuregulin, neuregulin polypeptide, neuregulin derivatives, or compounds which mimic the activities of neuregulins is at least 10^{-8} M.
- 20 24. Use of neuregulin, neuregulin polypeptide, neuregulin derivatives, or compounds which mimic the activities of neuregulins in the manufacture of a medicament for the treatment or management of heart disease and heart failure.

25

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 38/19, 48/00, A61P 9/00	A1	(11) International Publication Number: WO 00/37095 (43) International Publication Date: 29 June 2000 (29.06.00)
(21) International Application Number: PCT/AU99/01137 (22) International Filing Date: 21 December 1999 (21.12.99) (30) Priority Data: PP 7850 21 December 1998 (21.12.98) AU (71) Applicant (for all designated States except US): THE VICTOR CHANG CARDIAC RESEARCH INSTITUTE [AU/AU]; St Vincent's Hospital, Suite 1, Level 4, 376 Victoria Street, Darlinghurst, NSW 2010 (AU). (72) Inventor; and (75) Inventor/Applicant (for US only): ZHOU, Mingdong [AU/AU]; Unit 42 81B Gerard Street, Cremorne, NSW 2090 (AU). (74) Agent: F B RICE & CO; 605 Darling Street, Balmain, NSW 2041 (AU).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: CARDIAC MUSCLE FUNCTION AND MANIPULATION (57) Abstract A method of causing cardiomyocyte growth and/or differentiation, the method comprising exposing a cardiomyocyte to neuregulin (NRG) thereby activating the MAP kinase pathway in the cardiomyocyte and causing growth and/or differentiation of the cardiomyocyte. Use of neuregulin, neuregulin polypeptide, neuregulin derivatives, or compounds which mimic the activities of neuregulins in the treatment or management of heart disease and heart failure in a mammal.		




Figure 1




Figure 2a




Figure 2b




Figure 3a




Figure 3b




Figure 3c




Figure 4a




Figure 4b




Figure 5a




Figure 5b




Figure 5c




Figure 5d
Substitute Sheet (Rule 26) RO/AU




Figure 6a





Figure 6b



PATENT
Docket No. 524012000200

DECLARATION FOR UTILITY PATENT APPLICATION

AS A BELOW-NAMED INVENTOR, I HEREBY DECLARE THAT:

My residence, post office address, and citizenship is as stated below next to my name.

I believe I am the original, first and sole inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled: CARDIAC MUSCLE FUNCTION AND MANIPULATION,

☒ was filed on October 23, 2001 as Application Serial No. 09/980,672 and identified as attorney docket No. 524012000200.

I HEREBY STATE THAT I HAVE REVIEWED AND UNDERSTAND THE CONTENTS OF THE ABOVE-IDENTIFIED SPECIFICATION, INCLUDING THE CLAIMS, AS AMENDED BY ANY AMENDMENT REFERRED TO ABOVE.

I acknowledge the duty to disclose information which is material to the patentability as defined in 37 C.F.R. § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed:

Application No.	Country	Date of Filing (day/month/year)	Priority Claimed?
PP 7850	AUSTRALIA	December 21, 1998	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

I hereby claim benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:

Application Serial No.	Filing Date

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

Application Serial No.	Filing Date	Status
PCT/AU99/01137 ✓	December 21, 1999 ✓	<input type="checkbox"/> Patented <input type="checkbox"/> Pending <input checked="" type="checkbox"/> Abandoned

I hereby appoint the following attorneys and agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

76 -
 Lisa A. Amii (Reg No. 48,199)
 Mehran Arjomand (Reg No. 48,231)
 Sanjay S. Bagade (Reg No. 42,280)
 Shantanu Basu (Reg No. 43,318)
 Vincent J. Belusko (Reg No. 30,820)
 Kimberly A. Bolin (Reg No. 44,546)
 Tyler S. Brown (Reg No. 36,465)
 A. Randall Camacho (Reg No. 46,595)
 Robert K. Cerpa (Reg No. 39,933)
 Alex Chartove (Reg No. 31,942)
 Thomas E. Ciotti (Reg No. 21,013)
 Matthew M. D'Amore (Reg No. 42,457)
 Peter Davis (Reg No. 36,119)
 Karen B. Dow (Reg No. 29,684)
 Carolyn A. Favorito (Reg No. 39,183)
 Hector Gallegos (Reg No. 40,614)
 Deborah S. Gladstein (Reg No. 43,636)
 Kenneth R. Glick (Reg No. 28,612)
 Johny U. Han (Reg No. 45,565)
 Alan S. Hodes (Reg No. 38,185)
 Kelvan P. Howard (Reg No. P48,999)
 Wayne Jaeschke, Jr. (Reg No. 38,503)
 Parisa Jorjani (Reg No. 46,813)
 Richard C. Kim (Reg No. 40,046)
 Lawrence B. Kong (Reg No. P49,043)
 Glenn Kubota (Reg No. 44,197)
 Michael J. Mauriel (Reg No. 44,226)
 Philip A. Morin (Reg No. P-45,926)
 Mabel Ng (Reg No. P48,922)
 Catherine M. Polizzi (Reg No. 40,130)
 Robert E. Scheid (Reg. No. 42,126)
 Terri Shieh-Newton (Reg No. 47,081)
 Stanley H. Thompson (Reg No. 45,160)
 Brenda J. Wallach (Reg No. 45,193)
 E. Thomas Wheelock (Reg No. 28,825)
 Eric Witt (Reg No. 44,408)
 David T. Yang (Reg No. 44,415)
 George C. Yu (Reg No. 44,418)

Randolph Ted Apple (Reg No. 36,429)
 Laurie A. Axford (Reg No. 35,053)
 Erwin J. Basinski (Reg No. 34,773)
 Richard R. Batt (Reg No. 43,485)
 Jonathan Bockman (Reg No. 45,640)
 Barry E. Bretschneider (Reg No. 28,055)
 Nicholas Buffinger (Reg No. 39,124)
 Mark R. Carter (Reg No. 39,131)
 Peng Chen (Reg No. 43,543)
 Thomas Chuang (Reg No. 44,616)
 Cara M. Coburn (Reg No. 46,631)
 Raj S. Davé (Reg No. 42,465)
 David Devernoe (Reg No. P-50,128)
 Stephen C. Durant (Reg No. 31,506)
 David L. Fehrman (Reg No. 28,600)
 Thomas George (Reg No. 45,740)
 Debra J. Glaister (Reg No. 33,888)
 Bruce D. Grant (Reg No. 47,608)
 Douglas G. Hodder (Reg No. 41,840)
 Charles D. Holland (Reg No. 35,196)
 Jill A. Jacobson (Reg No. 40,030)
 Madeline I. Johnston (Reg No. 36,174)
 Ararat Kapouytian (Reg No. 40,044)
 Cameron A. King (Reg No. 41,897)
 Kawai Lau (Reg No. 44,461)
 Rimas T. Lukas (Reg No. 46,451)
 Gladys H. Monroy (Reg No. 32,430)
 Kate H. Murashige (Reg No. 29,959)
 Martin M. Noonan (Reg No. 44,264)
 Phillip Reilly (Reg No. 41,415)
 Debra A. Shetka (Reg No. 33,309)
 Kevin R. Spivak (Reg No. 43,148)
 Thomas L. Treffert (Reg No. P48,279)
 Michael R. Ward (Reg No. 38,651)
 Todd W. Wight (Reg No. 45,218)
 Frank Wu (Reg No. 41,386)
 Peter J. Yim (Reg No. 44,417)
 Karen R. Zachow (Reg No. 46,332)

and:

Please direct all communications to:

Peng Chen
Morrison & Foerster LLP
3811 Valley Centre Drive, Suite 500
San Diego, CA 92130-2332

Please direct all telephone calls to Peng Chen at (858) 720-5117.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Feb. 8, 2002
Date
MINGDONG ZHOU Mingdong Zhou
Name Mingdong ZHOU
Residence La Jolla, California 92037 CA
Citizenship Australia
Post Office Address 8430 Via Mallorca, Apt # E, La Jolla, CA 92037

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

(A) NAME: The Victor Chang Cardiac Research
Institute
(B) STREET: St Vincent's Hospital, Level 4, Suite 1,
376 Victoria Street
(C) CITY: Darlinghurst
(D) STATE: New South Wales
(E) COUNTRY: Australia
(F) POSTAL CODE (ZIP): 2010

(ii) TITLE OF INVENTION: Cardiac Muscle Function and
Manipulation

(iii) NUMBER OF SEQUENCES: 2

(iv) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30
(EPO)

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 114 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

AGCCATCTTG TAAATGTGCG GAGAAGGAGA AAACCTTTCTG TGTGAATGGA
GGGGAGTGCT 60

TCATGGTGAA AGACCTTTCA AACCCCTCGA GATACTTGTA AGGAGCTGTA CCAG
114

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 58 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Ser	His	Leu	Val	Lys	Cys	Ala	Glu	Lys	Thr	Phe	Cys	Val	Asn	Gly
Gly														
1				5					10					15
Glu	Cys	Phe	Met	Val	Lys	Asp	Leu	Ser	Asn	Pro	Ser	Arg	Tyr	Leu
Cys														
			20					25					30	
Lys	Cys	Pro	Asn	Glu	Phe	Thr	Gly	Asp	Arg	Cys	Gln	Asn	Tyr	Val
Met														
			35					40					45	
Ala	Ser	Phe	Tyr	Lys	Ala	Glu	Glu	Leu	Tyr					
	50					55								